SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

India’s pharma exporters facing intense competition from China

20 Dec 2011 Evaluate

Indian Pharmaceutical exporters are facing tough competition especially in Bulk drugs sector in international markets from China said Minister of State (MoS) for Commerce and Industry, Jyotiraditya Scindia in a written reply in Lok Sabha. According to the UN Comtrade data, Indian exporters exported $1034.04 million worth of Bulk drugs in the year 2010 against China’s $6040.26 million in the same period. While the Brazil remained a distant third in the Bulk drug exports with $82.27 million worth of exports in 2010.

Further, Indian exporters exported $6093.22 million worth of Formulations in the year 2010 being the leading exporter in the sector among the BRIC nations which includes Brazil, Russia, China and itself. However, China’s Formulations exports continued to rise at a brisk pace as it grew by over 31% to $4461.17 million in 2010 from $3397.26 million in 2009. Meanwhile, India is also facing competition from Brazilian companies in Latin American Countries.

Jyotiraditya Scindia also said that government has prepared strategies to achieve an export target of $25 billion in pharma sector by 2013-14 despite facing a stiff competition from China and Brazil. All three countries -- India, China and Brazil -- are members of the four-nation bloc of emerging economies called BRIC with R standing for Russia.

The minister of state also said that as per extant FDI policy, FDI, up to 100% under the automatic route, is permitted for Greenfield investments in the pharmaceuticals sector, while FDI, up to 100%, is permitted for brown field investments (i.e. investments in existing companies), in the pharmaceuticals sector, under the Government approval route.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×